100 results about "Premalignant Neoplasm" patented technology

This invention discloses a composite nanodelivery system encapsulated in a fusion membrane, its preparation method, and its applications. The nanodelivery system comprises a Ti3C2 / TiO2 / CuInS2 composite material, oxaliplatin loaded thereon, and a fusion membrane encapsulating the outer layer; the fusion membrane is formed by the fusion of Fusobacterium nucleatum extravesicles and M1 macrophage membranes. This invention also discloses a method for preparing the nanodelivery system, including the steps of preparing the Ti3C2 / TiO2 / CuInS2 composite material, preparing the fusion membrane, loading oxaliplatin, and encapsulating it in the fusion membrane. The nanodelivery system prepared by this invention exhibits pH-responsive drug release characteristics, generating H2S in the tumor microenvironment and H2 under light irradiation, while also possessing photocatalytic activity. This invention combines chemotherapy, photoelectrocatalytic therapy, and the regulation of multiple active substances, and can be used to prepare drugs for treating malignant tumors of the digestive system.

This invention provides the application of Jiawei Xihuang Pill (MXHP) in the preparation of drugs for the prevention and / or treatment of malignant tumors. This invention also provides the application of Jiawei Xihuang Pill in combination with chemotherapy drugs for the prevention and / or treatment of malignant tumors, particularly glioblastoma multiforme (GBM), wherein the active ingredients of Jiawei Xihuang Pill are prepared from bezoar, musk, vinegar-processed frankincense, vinegar-processed myrrh, and Panax notoginseng root extract in a weight ratio of 14-16:14-16:545-555:545-555:245-255. MXHP can synergistically inhibit the growth of glioblastoma in situ and induce tumor cell apoptosis, indicating that MXHP may be a potential therapeutic drug. Furthermore, compared to XHP, MXHP significantly prolongs the median survival of GBM, exhibiting an enhanced anti-GBM effect.

The disclosure belongs to the technical field of medicine. Provided are a CD97 and GSDME interaction inhibitor having anti-tumor activity and an application thereof. A compound screened in the disclosure enhances the susceptibility of NK cells to kill tumor cells by inhibiting the interaction between GSDME and CD97 in tumor cells, so as to induce an immune anti-tumor effect. Moreover, the compound enhances the susceptibility of tumor cells to pyroptosis by blocking the protective effect of CD97 on cleavage of GSDME proteins. Therefore, the compound can be used for treating GSDME and CD97 double-positive malignant tumors, and combined chemotherapy, immunotherapy, etc., to enhance the susceptibility of malignant tumors to chemotherapy and immunotherapy, prolonging the overall survival period of patients with malignant tumors. Specifically provided is a compound having a structure set forth in formula (I), a pharmaceutically acceptable salt, a solvent compound or a deuterated compound thereof.

This invention discloses a PROTAC chimera for targeted degradation of ALKBH5, its preparation method, and its applications. The structural formula of the PROTAC chimera is shown in Formula I. The PROTAC chimera provided by this invention achieves specific ubiquitination modification and proteasome-dependent degradation of the ALKBH5 protein, completely eliminating the target protein function from its source. This invention overcomes the inherent limitations of traditional small molecule inhibitors, which can only reversibly block ALKBH5 enzyme activity, cannot eliminate the target protein, easily induce compensatory upregulation of the target protein, and develop drug resistance. It provides a novel and precise targeted therapy strategy for ALKBH5-driven malignant tumors.

The invention relates to a medical instrument for gynecologic operation, in particular to a uterus traction device capable of avoiding tumor cell diffusion and a using method thereof.The traction device comprises a bag, the bag is provided with a closed end used for wrapping the bottom of the uterus and an open end used for facing the cervix uteri opening, and the bag is provided with an opening. The open end is provided with an adjusting and tightening mechanism, the cervix uteri, the uterus body and the double accessories of the cervix uteri and the uterus body can be wrapped in the bag by pulling the open end, and then the open end is tightened through the adjusting and tightening mechanism. A wrapping path in the direction from the bottom of the uterus to the cervix uteri opening is adopted, it is ensured that the uterus and contents of the uterus are completely wrapped and isolated in the bag by tightening the opening end, the operation concept that isolation is carried out in advance is achieved, the operation view is protected in the whole process, and tumor-free traction in the operation process is facilitated; in addition, the risks of incision planting and abdominal cavity spreading in malignant tumor surgery can be greatly reduced, the possibility of tumor cell spreading is avoided, and iatrogenic injury is reduced.

The present invention belongs to the technical field of medicine, and specifically relates to the use of a compound as represented by the following formula (I) or a pharmaceutically acceptable salt, isomer, or crystal form thereof in the preparation of a drug for preventing or treating malignant B cell tumors.

The invention relates to the technical field of biological medicines, and particularly discloses siRNA for inhibiting CD44v6 expression in tumors and application of the siRNA. The siRNA molecule can specifically target mRNA of CD44v6, and efficient knock-down is achieved on the gene level and the protein level (the interference efficiency reaches 70%-90%); in-vitro experiments prove that the siRNA can significantly inhibit the proliferation ability and clone formation ability of gastric cancer cells (such as AGS and HGC-27); in-vivo and in-vitro experiments further show that the siRNA can enhance the sensitivity of gastric cancer cells to a ferroptosis inducer RSL3 and generate a synergistic anti-tumor effect. The invention further provides a pharmaceutical composition containing the siRNA and application of the pharmaceutical composition in preparation of drugs for treating malignant tumors such as gastric cancer, and a new strategy and means are provided for overcoming the problem that tumor progression is fast.

This invention discloses a radioactive molecular probe for targeting CSPG4 / NG2, its preparation method, and its application. The radioactive molecular probe comprises the structure shown in Formula I or Formula II. The technical solution of this invention uses a radioactive molecular probe to specifically recognize CSPG4 / NG2 in vivo through the target polypeptide portion, thereby achieving specific nuclear medicine positron emission tomography (PET) or single-photon emission computed tomography (SPECT) imaging diagnosis of CSPG4 / NG2 positive tumors or CSPG4 / NG2 positive lesions, such as autoimmune diseases and cardiovascular and cerebrovascular diseases, thereby realizing early diagnosis and efficacy evaluation of malignant tumors.

This provides an improved method for treating malignant tumors in human patients. [Solution] A method comprising administering a therapeutically effective dose of a LAG-3 inhibitor; a PD-1 pathway inhibitor; and an immunotherapy agent.

This invention provides a hypoxia-mediated mechanism of malignant tumor formation, a treatment simulation method, and a system, relating to the field of biomathematical modeling technology. The method includes: dividing the tumor into a core region and a peripheral region, defining the core differences between the two regions in their microenvironmental composition, and forming a conceptual interaction network; establishing a state variable system centered on the number of tumor cells, constructing a mathematical model integrating tumor core-periphery heterogeneity, hypoxia-mediated processes, and immunosuppression cycles; solving the mathematical model, calculating the changes of each state variable over time under different initial conditions or intervention parameters, and outputting simulation results characterizing tumor growth and the state of the immune microenvironment; this invention, through the multi-level regulation of cell proliferation, immunosuppression cycles, and angiogenesis signals by oxygen concentration gradients, more realistically reproduces the spatial heterogeneous growth dynamics of solid tumors in vivo, and simulates the formation and maintenance mechanism of a strong immunosuppressive state in the tumor core region.

This invention discloses a methylation marker for the differential diagnosis of malignant and benign breast tumors. The invention provides the application of the methylated SH3PXD2B gene as a marker in product preparation; the product is used for at least one of the following purposes: (1) distinguishing between benign and malignant breast tumors; (2) distinguishing between benign breast tumors and different subtypes or stages of malignant breast tumors; (3) distinguishing between different subtypes or stages of malignant breast tumors. This invention has significant scientific and clinical application value for differentiating between benign and malignant breast tumors, different subtypes or stages of malignant breast tumors, and guiding the development of reasonable clinical treatment plans.

Disclosed is the use of a composition comprising a TET pathway inhibitor and a ferroptosis inducer in the manufacture of a medicament for the treatment of malignant tumors. It is found that TET1 up-regulates expression of a ferroptosis key regulation gene GCH1 through an NF [kappa] B signal, promotes synthesis of BH4, activates a GPX4 non-dependent pathway, and plays a key hub role in controlling ferroptosis sensitivity. Through combined use of TET pathway inhibitors (including a TET inhibitor and a BH4 synthesis inhibitor), the sensitivity of tumor cells to the ferroptosis inducer can be significantly improved, and the in-vivo use dosage of the ferroptosis inducer is reduced to 1% (1 mg / kg) of the conventional treatment dosage. The composition of the TET pathway inhibitor and the ferroptosis inducer, provided by the invention, can be used for remarkably improving the ferroptosis induction curative effect of various malignant tumors, particularly ferroptosis insensitive tumors, and enhancing the safety and universality of ferroptosis induction treatment.

The invention discloses a 2-amino-4-aromatic heterocyclic-1, 3, 5-triazine compound and application thereof, and the 2-amino-4-aromatic heterocyclic-1, 3, 5-triazine compound has the following structural general formula as shown in the specification, wherein W, X, Y and Z are independently selected from carbon or nitrogen. The 2-amino-4-aromatic heterocyclic-1, 3, 5-triazine compound designed and synthesized by the invention is a novel NF-kappa B induced kinase (NIK) inhibitor and is suitable for drug development taking INIK as a target spot, and the obtained drug can be used for treating malignant tumors such as leukemia, multiple myeloma glioma and the like.

The present invention relates to systems and methods for classification of cancer from gene expression input data. The method including: receiving a training dataset including nucleic acid data points from one or more samples; identifying classes in the training dataset including performing recursive clustering by, at each successive iteration, performing a search to identify clusters based on similarity, wherein each class of the classes is associated with a tumor; training a machine learning model to associate the nucleic acid data points of the training dataset with the identified classes; receiving the gene expression input data for classification; classifying, using the trained machine learning model, the gene expression input data as one or more of the identified classes; and outputting the classification of the gene expression input data.

The present invention disclosures a novel purine derivatives represented by formula (I) or a pharmaceutically acceptable salt thereof, intermediate and application thereof inpreparation of a medicament for treating or preventing a cancer. This compound is a novel PI3K inhibitor with an excellent inhibitory activity, and may be useful for treating a variety of malignant tumors.

The present invention features fratricide resistant modified immune cells (e.g., T- or NK-cells) having enhanced anti-neoplasia activity and methods for producing and using the same. Methods of treating neoplasia (e.g., T- or NK-cell malignancies) using fratricide resistant modified immune cells are also provided.

The present invention provides an antitumor agent for treating a malignant tumor patient expressing EGFR having at least one mutation selected from the group consisting of L718X mutation in exon 18 and L792X mutation in exon 20, wherein X represents an arbitrary amino-acid residue, the antitumor agent comprising(S)—N-(4-amino-6-methyl-5-(quinolin-3-yl)-8.9-dihydropyrimido[5.4-b]indolizin-8-yl)acrylamide (Compound (A)) or a salt thereof.

FIELD: oncology.SUBSTANCE: used to treat malignant embryonic tumors. The method involves pharmacological inhibition of factors that support tumor growth. A progesterone receptor antagonist is administered and immunological activation of the body's response against progesterone-induced blocking factor (PIBF), placental growth factor (PIGF) and trophoblastic β 1-glycoprotein.EFFECT: increased treatment reliability due to a comprehensive and selective effect on the tumor, simultaneous influence on both the primary tumor site and metastases, a reduction in the likelihood of relapse due to the destruction of the tumor vascular network, and a reduction in the overall toxic load on the patient's body during treatment.7 cl, 1 tbl, 5 ex

The application discloses damaged mitochondria as a malignant tumor metastasis prediction marker, and an application and detection system thereof, and is used for solving the problems of lacking specific prediction indexes and efficient and feasible prediction means for predicting malignant tumor metastasis in the prior art. The application rapidly enriches mitochondria from a to-be-detected plasma sample, detects the concentration of the prediction marker damaged mitochondria, and predicts the malignant tumor metastasis risk of a patient corresponding to the to-be-detected plasma sample based on the concentration of the prediction marker damaged mitochondria, so that whether the tumor patient will have metastasis in the future can be simply, rapidly and accurately predicted.

The application discloses a novel radionuclide therapeutic drug targeting nucleolus DDX24 helicase and a preparation method and application thereof. 64 The Cu-DOTA-TDP-2 has good tumor targeting uptake specificity, and is expected to provide a precise molecular imaging method for esophageal squamous cell carcinoma and other DDX24 high-expression malignant tumors; the novel radionuclide targeted drug 177 The Lu-DOTA-TDP-2 has high radiochemical yield and specific activity, good chemical stability, high affinity for DDX24 helicase, and a simple and easy-to-operate preparation method, and can be used for the treatment of DDX24 high-expression malignant tumors; the novel radionuclide targeted drug 177 The Lu-DOTA-TDP-2 has excellent biological safety performance and good tumor inhibition effect in esophageal squamous cell carcinoma and other DDX24 high-expression malignant tumors.

The application belongs to the technical field of biological probes, and relates to a PD-L1 guided specific targeted CTC detection combined with tumor boundary distinguishing biological probe and a preparation method thereof. The PD-L1 guided specific targeted CTC detection combined with tumor boundary distinguishing biological probe comprises a core, a covalent organic framework and a PD-L1 antibody, the core comprises a superparamagnetic nanoparticle, the covalent organic framework is coated on the surface of the core, and the PD-L1 antibody is combined on the surface of the covalent organic framework. The PD-L1 guided specific targeted CTC detection combined with tumor boundary distinguishing biological probe prepared by the application can be transported into the body across the membrane, smoothly enter a PD-L1 positive malignant tumor lesion, and perform Raman imaging to microscopically distinguish the tumor boundary.

The invention discloses a pharmaceutical composition for resisting NQO1 high-expression malignant tumors and application of the pharmaceutical composition, and relates to the technical field of medicines. When the vitamin K3, the vitamin K4 or the pharmaceutically acceptable salts thereof are combined with the quinone compounds for use, the killing sensitivity of NQO1 high-expression malignant tumor cells to the quinone compounds is obviously enhanced, and an explosive synergistic or synergistic anti-tumor effect is initiated; the killing effect of various quinone compounds on NQO1 high-expression malignant tumor cells is remarkably improved, so that the application dosage of the quinone compounds is reduced to reduce side effects, and the effect of killing NQO1 high-expression tumor cells with low dosage and high efficiency is achieved.

This invention is directed to compositions comprising bisantrene, particularly formulations of bisantrene dihydrochloride, wherein the formulations are suitable for intravenous administration into peripheral veins as well as methods for their use and methods for preparation of such compositions. The compositions according to the present invention eliminate the need to administer bisantrene by central venous catheter administration. The compositions can be used to treat malignancies and other conditions, and may be used for cardioprotection in patients undergoing chemotherapy with anthracycline-based anti-neoplastic agents. The inclusion of α-hydroxy acids in compositions according to the present invention improves the stability of such compositions and prevents precipitation of the bisantrene.

Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as gastric cancer.

The application discloses an automatic vagina closing and cutting instrument under a laparoscope and belongs to the technical field of medical instruments. The instrument comprises an operation handle, a sleeve, a clamping assembly, a cutting assembly, a rotating sleeve, a liquid storage sleeve, an adapter assembly, a protective sleeve and a sealing assembly. The sleeve is fixed to the outer side of the output end of the operation handle. The clamping assembly is arranged on the inner side of one end of the sleeve. The cutting assembly is used for cutting the vagina. The rotating sleeve is arranged outside the sleeve. The liquid storage sleeve is arranged on one end of the rotating sleeve and is in sliding connection with the sleeve. The adapter assembly is arranged on the inner side end of the liquid storage sleeve. One end of the protective sleeve is fixedly connected with the end of the liquid storage sleeve, which is far away from the operation handle. The fitting assembly is used for increasing the fitting property of the protective sleeve and the residual end of the vagina. The sealing assembly is arranged in the opening end of the protective sleeve. The movable protective sleeve is arranged outside the sleeve. The protective sleeve is tightly fitted with the residual end of the vagina through the fitting assembly. The risk that tumor cells enter the abdominal cavity through the open vagina is effectively blocked. The probability of abdominal cavity implantation and metastasis in the malignant tumor operation is remarkably reduced.

The invention discloses a malignant tumor postoperative washing agent as well as a preparation method and application thereof. The method comprises the following steps: taking hematoxylon decoction pieces, adding water, heating, refluxing and extracting to obtain an extracting solution, filtering the extracting solution, and concentrating filtrate to obtain a concentrated solution; adding ethanol into the concentrated solution, standing and precipitating, and carrying out suction filtration or centrifugation to obtain a first supernatant; recovering ethanol in the first supernatant under reduced pressure to obtain a sappan wood water extract liquid medicine; supplementing water into the hematoxylon water extract liquid medicine, and adjusting the liquid medicine ratio to a preset value; adding an antioxidant, stirring and dissolving, standing, and filtering to obtain a second supernatant; adding water into the second supernatant, and adjusting the liquid medicine ratio to a preset value; and then adding an excipient, and stirring for dissolving. The malignant tumor postoperative washing agent with the sappan wood extract as the active ingredient is used for local washing of surgical wounds, shows a killing effect on various cancer cells, and can effectively remove residual tumor cells, so that postoperative recurrence and metastasis of tumors are prevented.

1. The name of the design product: afterloading therapy machine. 2. The use of the design product: for the brachytherapy of human malignant tumor. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view.

The invention discloses a polypeptide SPIRM and an application thereof. It is found for the first time that lncRNA VPS9D1-AS1 has coding capacity, contains a 105bp small open reading frame, has a nucleotide sequence as shown in a sequence table SEQ ID NO: 2 and can translate a novel polypeptide (named as SPIRM) with the length of 34 amino acids, and the amino acid sequence of coded protein of the novel polypeptide is as shown in the sequence table SEQ ID NO: 1. The expression level of the polypeptide SPIRM can be used as a new biomarker to help diagnosis of malignant tumors including kidney cancer, brain glioma, liver cancer, thyroid cancer or adrenal cortex cancer, the polypeptide SPIRM can be used as a potential drug for treating malignant tumors, and a new thought and prospect are provided for development of novel antitumor drugs.

The invention discloses a multi-disease prediction method, system and device based on deep learning and a medium. The method comprises the steps that multi-mode historical medical data such as mammary gland X-rays, pelvic ultrasound and MRI are acquired and preprocessed; inputting the preprocessed data into a model including feature extraction, medical knowledge graph, causal reasoning and multiple disease prediction branches for training; preprocessing real-time medical data of the target user; and inputting the trained model to obtain a prediction result. According to the application, multi-modal data are integrated, the prediction precision of various diseases is improved through multi-module cooperation, the missed diagnosis rate is reduced, the medical burden is reduced, the screening efficiency and the population coverage rate are improved, and finally early discovery and intervention of female multi-malignant tumors are realized.